Cancers
Cancers represent a complex and heterogeneous group of diseases characterized by uncontrolled cell growth and the potential to invade other parts of the body. Despite significant advancements, many cancer types remain challenging to manage, necessitating the ongoing pursuit of novel therapeutic strategies. Protheragen is actively engaged in pioneering innovative compounds and therapeutic approaches that target the MyD88 pathway, aiming to address critical unmet needs in the research and preclinical development of oncology solutions.
Overview of Cancers
Cancers are fundamentally diseases of unchecked cellular proliferation, where abnormal cells divide without control and can infiltrate healthy tissues. This broad category encompasses over a hundred different diseases, each with unique genetic alterations, biological behaviors, and clinical manifestations. The complexity of cancer, including its ability to evade immune surveillance, resist therapies, and metastasize, underscores the urgent need for new insights and effective interventions.
MyD88 in Cancers Pathogenesis
The pathogenesis of cancer involves a multi-step process driven by genetic mutations, epigenetic alterations, and dysfunctional cellular signaling pathways that promote malignant transformation. A pivotal component in this intricate network, increasingly recognized for its role in cancer biology, is Myeloid Differentiation Primary Response 88 (MyD88). MyD88 serves as a crucial adaptor protein, indispensable for signal transduction downstream of most Toll-like Receptors (TLRs) and the interleukin-1 receptor (IL-1R) family.
Fig.1 MYD88 L265P mutation in B-cell malignancies and targeted therapy. (Roschewski, Phelan and Jaffe, 2024)In numerous cancer types, aberrant activation of TLR/IL-1R pathways, mediated by MyD88, is recognized as a significant contributor to tumor progression, inflammation within the tumor microenvironment, and even resistance to certain therapies. For instance, dysregulated MyD88 signaling can promote cancer cell survival, proliferation, angiogenesis, and metastasis. It can also shape the immune landscape of the tumor, influencing the recruitment and function of immune cells that either suppress or promote tumor growth. Targeting MyD88 is viewed as offering a compelling research strategy to modulate these pro-tumorigenic pathways and mitigate cancer pathology.
Targeting MyD88 for the Therapeutic Development in Cancers
| Drug Name | Indication | Mechanism of Action | Key Progress | Development Stage |
| Ursolic Acid | Colorectal Cancer | Downregulates MyD88, inhibits TLR4/MyD88/NF-κB signaling, reduces MMP-2/MMP-9 expression | Suppressed MyD88 expression and invasion in HCT-116 cells; inhibited hepatic metastasis in murine models | Preclinical |
| TJ-M2010-5 | Liver/Colorectal Cancer | Binds MyD88 TIR domain to prevent dimerization, blocking NF-κB activation | Extended survival over 40% in hepatocellular carcinoma models; significantly reduced serum IL-6 | Preclinical |
| ST2825 | Lymphoma/Pancreatic Cancer | Inhibits MyD88 homodimerization, blocks IRAK1/4 recruitment, induces tumor apoptosis | Reduced lymphoma growth by 53%; enhanced gemcitabine efficacy in pancreatic cancer | Preclinical |
| Sinomenine | Breast Cancer | Suppresses TLR2/4-MyD88-NF-κB pathway, decreases VEGF secretion | Reduced VEGF expression in MDA-MB-231 cells; inhibited M2 macrophage polarization in TME | Preclinical |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Protheragen delivers integrated, one-stop solutions for the development of novel compounds and therapies targeting MyD88 across oncology indications. Our team of expert scientists leverages cutting-edge technologies to accelerate the discovery and preclinical development process, offering specialized therapeutic discovery and disease model developmentservices precisely tailored to your project needs.
MyD88-Targeted Cancers
Protheragen leverages its specialized insight into MyD88 pathway biology to drive the research and development of compounds for diverse cancer types critically impacted by MyD88. By virtue of our team's detailed understanding of each condition's unique pathological profile, Protheragen crafts bespoke solutions that propel the discovery and practical application of impactful MyD88-targeted approaches for:
Therapeutic Discovery Platform for Cancers
Protheragen's robust therapeutic discovery services encompass the entire spectrum of drug discovery and preclinical advancement, with a specific emphasis on MyD88-related targets:
Disease Models Development for Cancers
Protheragen offers a comprehensive suite of advanced disease model development services for the precise assessment of MyD88-targeted therapeutic candidates' efficacy and safety.
Protheragen specializes in providing integrated preclinical development services dedicated to advancing MyD88-targeted therapeutic candidates for oncology indications. Our end-to-end capabilities streamline the drug development pipeline, from initial target identification and disease model development to in-depth pharmacokinetics and drug safety evaluation. Other focuses include investigator-initiated trials aimed at expediting the primary assessment stage.
If you are interested in our services, please don't hesitate to contact us.
References
- Roschewski, M., J. D. Phelan, and E. S. Jaffe. "Primary Large B-Cell Lymphomas of Immune-Privileged Sites." Blood 144.25 (2024): 2593-603.
- Yu, X., et al. "Myd88 L265p Mutation in Lymphoid Malignancies." Cancer Res 78.10 (2018): 2457-62.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.